
    
      The RTB101-211 study is a Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of
      RTB101 as COVID-19 Post-Exposure Prophylaxis in Asymptomatic Adults Age â‰¥65 Years who: have
      SARS-CoV-2 detected on a surveillance nasal or nasopharyngeal swab OR live in the same house
      or apartment as someone who has laboratory-confirmed symptomatic COVID-19. The study is
      designed to obtain study feasibility data for RTB101 in an unbiased fashion and will inform
      the design of a subsequent pivotal trial.
    
  